GridGain® Announces Beta Release of GridGain Cloud
In-Memory Cache-as-a-Service with SQL, Key-Value, and REST APIs
FOSTER CITY, Calif., June 14, 2018 (GLOBE NEWSWIRE) -- GridGain Systems, provider of enterprise-grade in-memory computing solutions based on Apache® Ignite(TM), today announced the beta release of GridGain Cloud. GridGain Cloud is the only in-memory cache-as-a-service that allows users to rapidly deploy a distributed in-memory cache and access it using ANSI-99 SQL, key-value or REST APIs. The result is in-memory computing performance in the cloud, which can be massively scaled out and can be deployed in minutes for caching applications. A free trial of the GridGain Cloud beta is available by visiting https://cloud.gridgain.com/.
Built on GridGain In-Memory Computing Platform
GridGain Cloud leverages key elements of the market-leading GridGain In-Memory Computing Platform to address cloud-based data caching use cases where performance and ease of deployment and management are of primary importance.
GridGain Cloud for Caching
GridGain Cloud, currently in beta, provides in-memory data caching capabilities that support GridGain Web Console (interactive SQL), REST APIs, JDBC, ODBC, and GridGain or Apache Ignite thin clients. With GridGain Cloud, any developer or analyst with a knowledge of SQL can launch a cluster with just a few mouse clicks. Users can then load data and monitor and manage the cluster from a central console. GridGain Systems will continue to add more capabilities during the beta over the coming months.
The beta of GridGain Cloud is free to try. Visit https://cloud.gridgain.com/.
According to 451 Research, by 2019, 60 percent of workloads will be deployed in cloud environments, including on-premises private clouds, hosted private clouds, IaaS and SaaS. The implication is that hybrid cloud environments will dominate for years to come. As a result, organizations developing digital transformation or omnichannel customer experience initiatives will need to ensure their applications scale across the hybrid infrastructure. They will also need to ensure real-time visibility into their data no matter where it resides to support their operational, transactional, regulatory and analytical requirements.
"GridGain Cloud represents an expansion of our in-memory computing solutions to support data-caching for cloud-native applications. For customers that do not require the broader functionality of our flagship GridGain In-Memory Computing Platform, GridGain Cloud offers the same in-memory performance and distributed scale for simpler use cases, coupled with the instant deployment and fully automated management that users expect from cloud-based services," said Abe Kleinfeld, president and CEO of GridGain Systems.
About GridGain® Systems
GridGain Systems is revolutionizing real-time data access and processing by offering an in-memory computing platform built on Apache® Ignite(TM). GridGain solutions are used by global enterprises in financial, software, e-commerce, retail, online business services, healthcare, telecom and other major sectors, with a client list that includes Barclays, ING, Sberbank, Finastra, IHS Markit, Workday, and Huawei. The GridGain in-memory computing platform delivers unprecedented speed and massive scalability to both legacy and greenfield applications. Deployed on a distributed cluster of commodity servers, GridGain software can reside between the application and data layers (RDBMS, NoSQL and Apache® Hadoop®), requiring no rip-and-replace of the existing databases, or it can be deployed as an in-memory transactional SQL database. GridGain is the most comprehensive in-memory computing platform for high-volume ACID transactions, real-time analytics, web-scale applications, artificial intelligence, and continuous learning and HTAP. The GridGain Cloud is a hosted in-memory computing solution for use cases that require powerful yet very easy-to-deploy solutions with SQL support. For more information, visit gridgain.com.
GridGain is a trademark or registered trademark of GridGain Systems, Inc. Apache, Apache Ignite, and Ignite are trademarks of The Apache Software Foundation. All other product and company names herein may be trademarks of their registered owners.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: GridGain Systems via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Corline Biomedical AB presenterar på Redeyes Growth Day 202026.5.2020 13:54:48 CEST | Pressemelding
Den 2 juni kl 14.00 presenterar Henrik Nittmar, VD i Corline Biomedical AB den senaste utvecklingen i bolaget på Redeye. Presentationen livesänds och kan följas på https://www.redeye.se/live/growth-day-2020 där presentationen även i efterhand kommer finnas tillgänglig, samt på vår bolagssida i Redeye Universe https://www.redeye.se/company/corline-biomedical. För mer information, vänligen kontakta Henrik Nittmar, VD Telefon: 018-71 30 90 E-post: firstname.lastname@example.org Certified Adviser Svensk Kapitalmarknadsgranskning Telefon: 011-32 30 732 E-post: email@example.com Corline Biomedical AB arbetar med den kroppsegna substansen heparin och har utvecklat en portfölj med läkemedelskandidater för användning i anslutning till organ- och celltransplantation. Bolaget planerar kliniska studier inom diabetes typ 1 och njurtransplantation, för vilket Corline även har erhållit särläkemedelsstatus (”Orphan Drug”). Inom ramen för helägda dotterbolaget Corline Pharma AB utvärderas in vivo-administrati
Corline Biomedical AB presenterar på Redeyes Temaevent Orphan Drugs26.5.2020 13:49:07 CEST | Pressemelding
Corline Biomedical AB (”Corline”) kommer att presentera sin verksamhet på Redeyes temaevent Orphan Drugs. Presentationen sker kl 11:30 den 27 maj 2020 i Stockholm och livesänds via Redeyes hemsida. Konferensprogrammet och livesändningen görs tillgängliga via Redeyes hemsida https://www.redeye.se/live/orphan-27-maj. För mer information, vänligen kontakta Henrik Nittmar, VD Telefon: 018-71 30 90 E-post: firstname.lastname@example.org Certified Adviser Svensk Kapitalmarknadsgranskning Telefon: 011-32 30 732 E-post: email@example.com Corline Biomedical AB arbetar med den kroppsegna substansen heparin och har utvecklat en portfölj med läkemedelskandidater för användning i anslutning till organ- och celltransplantation. Bolaget planerar kliniska studier inom diabetes typ 1 och njurtransplantation, för vilket Corline även har erhållit särläkemedelsstatus (”Orphan Drug”). Inom ramen för helägda dotterbolaget Corline Pharma AB utvärderas in vivo-administration av Corlines heparinsubstans och sedan tidigare
Lundin Gold Inc. Announces C$50 Million Bought Deal Financing26.5.2020 13:30:02 CEST | Press release
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION TO UNITED STATES VANCOUVER, British Columbia, May 26, 2020 (GLOBE NEWSWIRE) -- Lundin Gold Inc. ("Lundin Gold" or the "Company") (TSX: LUG, Nasdaq Stockholm: LUG) has announced today that it has entered into an agreement with BMO Capital Markets (“BMO”), under which BMO has agreed to buy on a bought deal basis 4,150,000 common shares (the “Common Shares”), at a price of C$12.05 per Common Share for gross proceeds of approximately C$50 million (the “Offering”). The Company has granted BMO an option, exercisable at the offering price for a period of 30 days following the closing of the Offering, to purchase up to an additional 15% of the Offering to cover over-allotments, if any. The offering is expected to close on or about June 11, 2020 and is subject to Lundin Gold receiving all necessary regulatory approvals. Newcrest Mining Limited, which currently holds approximately 32% of the Company’s issued and outsta
PCI Biotech: Disclosure of voting rights for Chairman of the Board26.5.2020 13:20:03 CEST | Press release
Oslo, 26 May 2020. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of its chairman, Hans Peter Bøhn. Hans Peter Bøhn is chairman of PCI Biotech and shall open the annual general meeting of the Company on 27 May 2020. Mr. Bøhn holds 123,662 shares, representing 0.3 per cent of the share capital of PCI Biotech. Mr. Bøhn has received powers of attorney to represent and vote for 7,171,710 additional shares. In total, Mr. Bøhn will represent and vote for 19.6 per cent of the share capital. A major part of the powers of attorney are without voting instructions. The powers of attorney are only valid at the annual general meeting on 27 May 2020. This information is subject to the disclosure requirements pursuant to section 4 -3, cf. section 5-12 of the Norwegian Securities Trading Act. Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Ronny Skuggedal, CFO, firstname.lastname@example.org, Mobile: +47 9400 5757
Prosafe SE: First quarter 2020 report – Adapting to a new reality26.5.2020 11:44:38 CEST | Press release
(Figures in brackets refer to the corresponding period of 2019) After several years of low activity across the industry, the company has presented a business plan and a restructuring proposal to lenders which – if approved as proposed – will result in a sustainable balance sheet. The revised business plan reflects a new reality in light of Covid-19, structural changes, oil price collapse, oversupply and anticipated impact on future activity and performance. Consequently, an impairment of USD 810.5 million was made to the book value of vessels in the quarter resulting in a negative book equity of USD 858.9 million by the end of the quarter. The company has sufficient liquidity of USD 184 million at the end of the quarter and continues to operate on a going concern basis on the assumption that there is justified hope to agree a sustainable financial solution with lenders. Recent highlights Prosafe implemented Covid-19 plans early to safeguard people and assets, and this has proven succes
Result of Riksbank reversed auctions SEK Municipal Bonds26.5.2020 11:30:00 CEST | Press release
Result of Riksbank reversed auctions SEK Municipal Bonds Results of auctions Municipal BondsAggregateAuction date5/26/2020Maturity2022Tendered volume, mln SEK750 +/- 750Volume offered, mln SEK1,600Volume bought, mln SEK100Number of bids4Number of accepted bids1Credit Class 1Maturity, QuarterQ1Maturity, QuarterQ2Maturity, QuarterQ3Maturity, QuarterQ4Volume Offered, mln SEK0Volume Offered, mln SEK0Volume Offered, mln SEK0Volume Offered, mln SEK0Volume bought, mln SEK0Volume bought, mln SEK0Volume bought, mln SEK0Volume bought, mln SEK0Number of bids0Number of bids0Number of bids0Number of bids0Number of accepted bids0Number of accepted bids0Number of accepted bids0Number of accepted bids0Average yield-Average yield-Average yield-Average yield-Lowest accepted yield-Lowest accepted yield-Lowest accepted yield-Lowest accepted yield-Highest yield-Highest yield-Highest yield-Highest yield-% accepted at lowest yield-% accepted at lowest yield-% accepted at lowest yield-% accepted at lowest yie